BETHESDA, Md., July 1, 2026
A National Institutes of Health (NIH)-funded study has identified a promising blood-based biomarker that could transform the early detection and management of Alzheimer’s disease (AD) by predicting when symptoms are likely to develop. Researchers discovered that elevated levels of specific circular RNAs (circRNAs) in blood samples were significantly more effective than the current leading biomarker, pTau217, at forecasting the transition from silent disease to symptomatic Alzheimer’s. The findings represent a major advancement in precision neurology, offering the potential to improve patient selection for clinical trials, optimize treatment timing, and enhance monitoring of disease progression. Unlike existing blood tests that primarily detect amyloid plaque pathology years or even decades before symptoms appear, the newly identified circRNA biomarkers appear to reflect ongoing biological changes that occur much closer to the onset of cognitive decline, creating new opportunities for earlier clinical intervention and more personalized treatment strategies.
Novel circRNA Biomarkers Outperform Existing Alzheimer’s Blood Tests
The NIH-supported research, led by Carlos Cruchaga, Ph.D., at Washington University School of Medicine, analyzed blood samples from more than 1,200 participants across multiple independent research cohorts. Investigators identified 34 circular RNAs (circRNAs) that were strongly associated with Alzheimer’s disease pathology. Predictive models built using these biomarkers performed similarly to pTau217, currently regarded as the leading blood-based biomarker for Alzheimer’s diagnosis. However, the circRNA-based model demonstrated a substantial advantage in predicting future disease progression.
Individuals with elevated circRNA levels were found to have nearly three times greater risk of developing Alzheimer’s symptoms, with biomarker changes becoming detectable approximately two to four years before cognitive impairment emerged. The findings were independently replicated in separate patient populations, strengthening confidence in the robustness and reproducibility of the results while highlighting circRNAs as highly promising biomarkers for monitoring disease progression.
Earlier Prediction Could Improve Clinical Trials and Patient Care
Advertisement
One of the most significant challenges in Alzheimer’s research has been identifying patients who are approaching symptom onset while they are still eligible for therapies designed to delay disease progression. Current amyloid-based blood tests provide reliable diagnosis but often become positive decades before symptoms appear, making them less useful for predicting when treatment should begin. Because circRNAs reflect more dynamic biological activity within the brain, researchers believe they may provide clinicians with a more accurate picture of disease evolution.
The new biomarker could significantly improve enrollment into Alzheimer’s clinical trials, allowing investigators to identify patients most likely to benefit from disease-modifying therapies while also improving evaluation of therapeutic effectiveness. Researchers also noted that patients receiving amyloid-removing therapies may become negative for conventional biomarkers despite continued disease progression, suggesting circRNAs may offer a more comprehensive assessment of underlying Alzheimer’s biology.
Advancing Precision Medicine for Alzheimer’s Disease
The research team is now collaborating with commercial partners to develop clinical-grade blood assays capable of translating these discoveries into routine healthcare practice. If successfully validated in larger prospective studies, circRNA testing could become an important addition to the growing arsenal of blood-based diagnostic tools for Alzheimer’s disease. The technology has the potential to support earlier intervention, improve monitoring of emerging therapies, and accelerate the development of next-generation treatments targeting neurodegenerative diseases.
Supported by multiple grants from the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke (NINDS), the study represents another major step toward precision medicine in Alzheimer’s care. As researchers continue to refine these innovative biomarkers, the findings offer renewed hope that earlier diagnosis and more personalized treatment approaches may ultimately improve outcomes for millions of people affected by Alzheimer’s disease worldwide.
Source: NIH press release
